BMS agrees to acquire Karuna Therapeutics for $14bn
Pharmaceutical Technology
DECEMBER 26, 2023
Bristol Myers Squibb (BMS) has signed a definitive agreement for the acquisition of Karuna Therapeutics for $14bn in cash.
Tue.Dec 26, 2023
243 
AZ makes another cell therapy play with $1.2bn Gracell buy
pharmaphorum
DECEMBER 26, 2023
AstraZeneca agrees a $1.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
KSQ-4279 by F. Hoffmann-La Roche for Ovarian Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
KSQ-4279 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Ovarian Cancer.
KarXT: A New Hope for Schizophrenia Patients, Phase III Trial Data Reveals
XTalks
DECEMBER 26, 2023
Karuna Therapeutics, a biopharmaceutical company dedicated to uncovering, advancing and providing groundbreaking medicines for individuals facing psychiatric and neurological conditions, has recently disclosed encouraging outcomes from the Phase III EMERGENT-2 trial of KarXT (xanomeline-trospium) in adults diagnosed with schizophrenia. “New treatments and novel mechanisms are urgently needed for people with schizophrenia because many don’t respond to their therapy and others only have a partial
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Difficult biotech investment ecosystem forces focus on value
Pharmaceutical Technology
DECEMBER 26, 2023
In 2023, investors pursued pharmaceutical assets with value amidst an unstable economic environment.
Investing in healthspan: A prescription for prosperity
pharmaphorum
DECEMBER 26, 2023
Exploring the powerful collaborations between scientists, investors, and the medical community in finding breakthrough treatments for major diseases, and the notion of 'healthspan'
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Exploring the reasons behind increasing burdens on clinical research sites
pharmaphorum
DECEMBER 26, 2023
In the first of a five-part festive instalment of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Advarra’s chief product officer, Elisa Cascade, about the reasons behind increasing burdens on clinical research sites over the last five years.
ABBV-400 by AbbVie for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
Which pharmaceutical companies have the most emulsion dosed drugs?
Drug Patent Watch
DECEMBER 26, 2023
This chart shows the pharmaceutical companies with the most emulsion dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most emulsion dosed drugs… The post Which pharmaceutical companies have the most emulsion dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Exarafenib by Kinnate Biopharma for Non-Small Cell Lung Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
Exarafenib is under clinical development by Kinnate Biopharma and currently in Phase I for Non-Small Cell Lung Cancer.
New patent for Purdue Pharma drug HYSINGLA ER
Drug Patent Watch
DECEMBER 26, 2023
Annual Drug Patent Expirations for HYSINGLA+ER Hysingla Er is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from one supplier. There are… The post New patent for Purdue Pharma drug HYSINGLA ER appeared first on DrugPatentWatch - Make Better Decisions.
AZD-9550 by AstraZeneca for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
AZD-9550 is under clinical development by AstraZeneca and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
New patent for Blueprint Medicines drug AYVAKIT
Drug Patent Watch
DECEMBER 26, 2023
Annual Drug Patent Expirations for AYVAKIT Ayvakit is a drug marketed by Blueprint Medicines and is included in one NDA. It is available from one supplier. There are three patents… The post New patent for Blueprint Medicines drug AYVAKIT appeared first on DrugPatentWatch - Make Better Decisions.
ADRX-0706 by Adcentrx Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
ADRX-0706 is under clinical development by Adcentrx Therapeutics and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
New patent expiration for Woodward drug COREG CR
Drug Patent Watch
DECEMBER 26, 2023
Annual Drug Patent Expirations for COREG+CR Coreg Cr is a drug marketed by Woodward and is included in one NDA. It is available from four suppliers. There are two patents… The post New patent expiration for Woodward drug COREG CR appeared first on DrugPatentWatch - Make Better Decisions.
GS-4528 by Gilead Sciences for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
GS-4528 is under clinical development by Gilead Sciences and currently in Phase I for Metastatic Renal Cell Carcinoma.
Top 5 Most Popular Cold Chain Articles of 2023
Pharmaceutical Commerce
DECEMBER 26, 2023
Items in this sector ranged touched on topics such as pharma shipping, container technology, and sustainability.
BGB-30813 by BeiGene for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
BGB-30813 is under clinical development by BeiGene and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
ORB-011 by Orionis Biosciences for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
ORB-011 is under clinical development by Orionis Biosciences and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
KB-707 by Krystal Biotech for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
KB-707 is under clinical development by Krystal Biotech and currently in Phase I for Solid Tumor.
ODM-212 by Orion for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
ODM-212 is under clinical development by Orion and currently in Phase I for Solid Tumor.
HEC-88473 by HEC Pharma for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
HEC-88473 is under clinical development by HEC Pharma and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
MPT-0118 by Monopteros Therapeutics for Breast Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
MPT-0118 is under clinical development by Monopteros Therapeutics and currently in Phase II for Breast Cancer.
MPT-0118 by Monopteros Therapeutics for Gastric Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
MPT-0118 is under clinical development by Monopteros Therapeutics and currently in Phase II for Gastric Cancer.
MPT-0118 by Monopteros Therapeutics for Chordoma: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
MPT-0118 is under clinical development by Monopteros Therapeutics and currently in Phase II for Chordoma.
BR-790 by Jiangxi Qingfeng Pharmaceutical for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
BR-790 is under clinical development by Jiangxi Qingfeng Pharmaceutical and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
TAK-500 by Takeda Pharmaceutical for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
TAK-500 is under clinical development by Takeda Pharmaceutical and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC).
BI-765179 by Boehringer Ingelheim International for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
BI-765179 by Boehringer Ingelheim International for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Cutaneous Squamous Cell Carcinoma (cSCC).
EXS-617 by Exscientia for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
EXS-617 is under clinical development by Exscientia and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC).
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content